Lusine Harutyunyan, Hematologist, R1 Researcher at Yeolyan Hematology and Oncology Center, and Adjunct Researcher at Immune Oncology Research Institute, shared a post on LinkedIn:
“On March 20, 2026 the FDA approved nivolumab in combination with AVD for adult and pediatric patients (≥12 years) with previously untreated stage III or IV classical Hodgkin lymphoma. At the same time, this systematic review was submitted in Frontiers in Oncology, further supporting the evidence for nivolumab’s effectiveness in the first-line setting.
I am happy to share this open-access publication, to which I had the pleasure of contributing as a co-author.”
Title: Clinical efficacy and safety of pembrolizumab and nivolumab in frontline treatment for classical Hodgkin lymphoma: systematic review and meta-analysis of clinical trials
Authors: Artem Oganesyan, Andrew Gregory, Mark Gregory, Deivid Badalian, Asatur Chakmanyan, Lusine Harutyunyan, Vahe Khachatryan, Abhay Aradhya, Aheed Javaid, Yervand Hakobyan, Christian J Fidler, Pierluigi Porcu
Read The Full Article
Other articles about lymphoma on OncoDaily.